X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

Mesoblast and NIH partner on 120-patient trial to treat end-stage heart failure

Yuvraj_pawp by Yuvraj_pawp
8th August 2014
in Americas, Clinical Trials, News

Australia-based regenerative medicine company Mesoblast has signed an agreement with the US National Institutes of Health’s (NIH) National Heart, Lung and Blood Institute to carry out a clinical trial using the company’s adult stem cell therapy for the treatment of patients with advanced heart failure.

The treatment is indicated for patients who require an implantable left ventricular assist device (LVAD) to maintain circulatory support.

The trial is also supported by the National Institute of Neurological Disorders and Stroke, part of the NIH, and the Canadian Institutes for Health Research.

The company’s mesenchymal precursor cells (MPCs) are used in end-stage heart failure patients to improve heart muscle function in order to reduce the need for LVAD support, and to reduce the long-term complications of LVAD implantation.

“We are pleased that the NIH has chosen to evaluate Mesoblast’s cell-based therapy in patients with the most advanced stage of heart failure, a complementary area to our ongoing Phase III programme in patients with earlier stage disease.”

Mesoblast chief executive Silviu Itescu said: “We are pleased that the NIH has chosen to evaluate Mesoblast’s cell-based therapy in patients with the most advanced stage of heart failure, a complementary area to our ongoing Phase III programme in patients with earlier stage disease.”

The NIH-funded Cardiothoracic Surgical Trials Network will be responsible for carrying out the trial, which will enrol 120 patients in more than 20 sites across the US.

The double-blind, placebo-controlled, two-to-one randomised trial is designed to evaluate the effects of a single injection of 150 million allogeneic, or off-the-shelf, MPCs into the hearts of patients with advanced heart failure.

The primary efficacy endpoint of the trial is the number of temporary weans from LVAD tolerated over 12 months. In addition, the trial will evaluate patient survival and re-hospitalisation over 12 months.

The new study builds on data from a double-blind study in 30 patients which showed the potential benefits of a single intra-cardiac injection of 25 million MPCs in advanced heart failure and LVAD implantation.

The company said that the 150 million MPC dose selected for direct cardiac injection in this second trial is the same dose that is currently being evaluated in an ongoing Phase III trial of about 1,700 patients with NYHA class II-III heart failure.

Sponsored by Mesoblast’s development and commercial partner, Teva Pharmaceutical Industries, the Phase III trial is actively enrolling patients across multiple sites in the US.

Tags: America
Previous Post

EnteroMedics Reports Second Quarter 2014 Financial Results

Next Post

Juno Closes $134M Series B Round

Related Posts

Drug Development

New Delivery Path Brings To Light Efficacy of Immunotherapy

1st April 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Next Post

Juno Closes $134M Series B Round

Latest News

Drug Development

New Delivery Path Brings To Light Efficacy of Immunotherapy

1st April 2023
Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In